Quam Securities

Since its inception in 1986, Quam Securities Limited (Quam Securities) has grown to become one of the few mid-tier securities brokerages in Hong Kong with global execution capabilities for both private and institutional clients. It boasts a well-established network in Greater China including Taiwan and in major world markets through the Global Alliance Partners (GAP). Quam Securities is well-positioned not only to harness and drive business within the China Tonghai International Financial Limited but also between China and the world markets.

Research from Quam Securities

Research from Quam Securities, Quam Securities

Quam Securities Research

Equity Bottom-Up

<ul><li>The company currently has a portfolio of over 50 innovative programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases.</li><li>Among these programs, 8 products are in the commercial stage.</li><li>The company has 2 first-in-class bispecific antibody products, cadonilimab and ivonescimab, launched in China, and they are included in the NRDL.</li></ul>

The company currently has a portfolio of over 50 innovative programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases.Among these programs, 8 products are in the commercial stage.The company has 2 first-in-class bispecific antibody products, cadonilimab and ivonescimab, launched in China, and they are included in the NRDL.

Akeso

Quam Morning Note (28 Aug) - Akeso